Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?
Targeted therapies have become a mainstay in the treatment of cancer, but their long‐term efficacy is compromised by acquired drug resistance. Acquired therapy resistance develops via two phases—first through adaptive development of nongenetic drug tolerance, which is followed by stable resistance t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13406 |